David Wu
Pulmonary Disease · Chicago, ILNPI 1699039438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AstraZeneca accounts for 79.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $228 and has fallen 51.4% since, to $111 in 2025. That places this record below the midpoint for pulmonary disease clinicians in IL, where the typical reported total is $1,325.
Across 49 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$691
- GSK$65
- Cook Medical LLC$37
- Mallinckrodt Hospital Products Inc.$30
- Pfizer$28
- Ferring Pharmaceuticals Inc.$21
What the payments were for
- Food & beverage$871100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $691 |
| GSK | 4 | $65 |
| Cook Medical LLC | 1 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Pfizer | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
How this compares
$871 in reported general payments places this provider in the 45th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 34 | $182,455 |
| Dupixent PenDupilumab | 24 | $86,585 |
| Spiriva RespimatTiotropium Bromide | 135 | $57,436 |
| BreynaBudesonide/Formoterol Fumarate | 121 | $20,948 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $20,377 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $6,138 |
| Pirfenidone | 19 | $5,207 |
| AlvescoCiclesonide | 54 | $4,771 |
| Mycophenolate Mofetil | 13 | $2,132 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $1,609 |
| Prednisone | 84 | $692 |
| Ethambutol Hcl | 16 | $649 |
| Fluticasone Propionate | 15 | $410 |
| Azithromycin | 29 | $356 |
| Doxycycline Monohydrate | 26 | $237 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.